Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Spectrum Health Hospitals
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Giselle Sholler, Spectrum Health Hospitals
ClinicalTrials.gov Identifier:
NCT00601003
First received: January 14, 2008
Last updated: September 8, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)